Organon & Co

OGN

Company Profile

  • Business description

    Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.

  • Contact

    30 Hudson Street
    Floor 33
    Jersey CityNJ07302
    USA

    T: +1 551 430-6900

    https://www.organon.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2026

    Employees

    10,000

Stocks News & Analysis

stocks

Sales shine but broader macro outlook darkens for this ASX share

US stores are struggling, but our investment thesis hinges on the Australian rollout.
stocks

Chart of the Week: US equity market trading at an attractive discount

The latest from our Chief US Market Strategist.
stocks

Undervalued ASX share retains wide moat rating despite regulatory pressures

Proposed price regulation impacts our fair value.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,168.9043.800.48%
CAC 408,245.8018.07-0.22%
DAX 4023,806.99273.64-1.14%
Dow JONES (US)48,301.90391.980.82%
FTSE 10010,603.485.40-0.05%
HKSE25,752.40140.62-0.54%
NASDAQ22,810.76175.760.78%
Nikkei 22555,895.32413.10-0.73%
NZX 50 Index13,273.8119.870.15%
S&P 5006,829.5246.710.69%
S&P/ASX 2008,973.2057.800.65%
SSE Composite Index3,966.1728.83-0.72%

Market Movers